Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below 50-Day Moving Average – Time to Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s stock price passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of C$14.30 and traded as low as C$13.35. Cipher Pharmaceuticals shares last traded at C$13.53, with a volume of 9,101 shares trading hands.

Cipher Pharmaceuticals Stock Down 2.1%

The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.67 and a current ratio of 1.59. The company has a market capitalization of C$336.75 million, a price-to-earnings ratio of 11.83 and a beta of 1.26. The business’s 50 day moving average is C$14.21 and its 200 day moving average is C$16.21.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Tuesday, August 11th. The company reported C$0.21 EPS for the quarter. The business had revenue of C$17.14 million during the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. Sell-side analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current year.

Insider Transactions at Cipher Pharmaceuticals

In other news, Director Craig Mull bought 20,000 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was purchased at an average cost of C$14.16 per share, with a total value of C$283,200.00. Following the acquisition, the director directly owned 1,009,953 shares in the company, valued at C$14,300,934.48. This trade represents a 2.02% increase in their ownership of the stock. Insiders own 42.00% of the company’s stock.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.